ES2117797T3 - Procedimiento para la preparacion de compuestos de benzodiazepina utilizados como antagonistas de la cck o de la gastrina. - Google Patents

Procedimiento para la preparacion de compuestos de benzodiazepina utilizados como antagonistas de la cck o de la gastrina.

Info

Publication number
ES2117797T3
ES2117797T3 ES94924368T ES94924368T ES2117797T3 ES 2117797 T3 ES2117797 T3 ES 2117797T3 ES 94924368 T ES94924368 T ES 94924368T ES 94924368 T ES94924368 T ES 94924368T ES 2117797 T3 ES2117797 T3 ES 2117797T3
Authority
ES
Spain
Prior art keywords
sup
sub
gastrine
cck
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94924368T
Other languages
English (en)
Inventor
Graeme Semple
Hamish Ryder
Michael Szelke
Masato Satoh
Mitsuaki Ohta
Keiji Miyata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Ferring BV
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd, Ferring BV filed Critical Yamanouchi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2117797T3 publication Critical patent/ES2117797T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Lubricants (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

UN DERIVADO DE LA FORMULA (I), O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN LA QUE: (A) R{SUP,4} ES UN GRUPO ALQUILO, CICLOALQUILO O ARILO; (B) R{SUP,10} SE SELECCIONA DEL HALO, OH, CH{SUB,3}, OCH{SUB,3}, NR{SUP,11}R{SUP,12}, NO{SUB,2}, NHCHO, CO{SUB,2}H Y CN Y R{SUP,11} Y R{SUP,12} SE SELECCIONAN INDEPENDIENTEMENTE DEL H Y ALQUILO (C{SUB,1}-C{SUB,5}) O JUNTO CON NR{SUP,11}R{SUP,12} FORMAN UNA ESTRUCTURA CICLICA (II), EN LA QUE A ES DE 1 A 6; Y (C) R{SUP,2} ES UN HETEROCICLO SUSTITUIDO O NO SUSTITUIDO, DE 5 O 6 ELEMENTOS, AROMATICO, QUE CONTIENE AL MENOS DOS HETEROATOMOS DE LOS CUALES AL MENOS UNO ES NITROGENO. ESTOS COMPUESTOS SON ANTAGONISTAS DE LA GASTRINA Y/O DEL RECEPTOR CCK-B.
ES94924368T 1993-08-25 1994-08-25 Procedimiento para la preparacion de compuestos de benzodiazepina utilizados como antagonistas de la cck o de la gastrina. Expired - Lifetime ES2117797T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9317693A GB2282595A (en) 1993-08-25 1993-08-25 Benzodiazepine derivatives

Publications (1)

Publication Number Publication Date
ES2117797T3 true ES2117797T3 (es) 1998-08-16

Family

ID=10741026

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94924368T Expired - Lifetime ES2117797T3 (es) 1993-08-25 1994-08-25 Procedimiento para la preparacion de compuestos de benzodiazepina utilizados como antagonistas de la cck o de la gastrina.

Country Status (21)

Country Link
US (1) US5728829A (es)
EP (1) EP0715624B1 (es)
JP (1) JPH09504005A (es)
KR (1) KR960703873A (es)
CN (1) CN1129442A (es)
AT (1) ATE164840T1 (es)
AU (1) AU687433B2 (es)
CA (1) CA2169089A1 (es)
CZ (1) CZ53096A3 (es)
DE (1) DE69409534T2 (es)
DK (1) DK0715624T3 (es)
ES (1) ES2117797T3 (es)
FI (1) FI960836A7 (es)
GB (1) GB2282595A (es)
HU (1) HUT73978A (es)
IL (1) IL110783A0 (es)
NO (1) NO960747L (es)
NZ (1) NZ271131A (es)
PL (1) PL313165A1 (es)
WO (1) WO1995006040A1 (es)
ZA (1) ZA946474B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69728688T2 (de) 1996-11-19 2004-08-19 Amgen Inc., Thousand Oaks Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
JP3999819B2 (ja) * 1996-12-10 2007-10-31 ゼリア新薬工業株式会社 １，５―ベンゾジアセピン誘導体
FR2782997A1 (fr) * 1998-09-08 2000-03-10 Hoechst Marion Roussel Inc Nouveaux derives de la benzodiazepinone, procede de preparation et intermediaires de ce procede, application a titre de medicaments et compositions pharmaceutiques les renfermant
WO2002092096A1 (en) * 2001-05-11 2002-11-21 Yamanouchi Pharmaceutical Co., Ltd. Antitumor agents
GB0221923D0 (en) * 2002-09-20 2002-10-30 Arrow Therapeutics Ltd Chemical compounds
WO2005000807A2 (en) * 2003-06-26 2005-01-06 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
AU2006255047B2 (en) * 2005-06-06 2011-09-15 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating sleep disorders
DK3071206T3 (da) 2013-11-22 2021-05-25 CL BioSciences LLC Gastrinantagonister (eg yf476, netazepid) til behandling og forebyggelse af osteoporose
GB201414116D0 (en) * 2014-08-08 2014-09-24 Trio Medicines Ltd Benzodiazepine derivatives
GB201513979D0 (en) * 2015-08-07 2015-09-23 Trio Medicines Ltd Synthesis of benzodiazepine derivatives
US10881667B2 (en) 2018-10-30 2021-01-05 City University Of Hong Kong Method and composition for treating epilepsy
CN109553591B (zh) * 2019-01-15 2020-12-15 山东安信制药有限公司 一种富马酸喹硫平中间体的制备方法
US11285161B2 (en) 2019-04-26 2022-03-29 City University Of Hong Kong Method and composition for treating mental disorder and pain associated with nerve damage
FR3097222B1 (fr) * 2019-06-11 2021-05-28 Michelin & Cie Nouveaux composes 1,3-dipolaires comprenant un heterocycle aromatique et un cycle imidazole
US20250186634A1 (en) * 2023-12-07 2025-06-12 Evergreen Discovery, LLC Methods of treating small cell lung cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
IL96613A0 (en) * 1989-12-18 1991-09-16 Merck & Co Inc Pharmaceutical compositions containing benzodiazepine analogs
FI932928A0 (fi) * 1990-12-25 1993-06-24 Yamanouchi Pharma Co Ltd Nya bensodiazepinderivat
GB9116113D0 (en) * 1991-07-25 1991-09-11 Merck Sharp & Dohme Therapeutic agents
FR2682381B1 (fr) * 1991-10-10 1995-04-07 Rhone Poulenc Rorer Sa Derives de benzodiazepine, leur preparation et les medicaments les contenant.
WO1993007131A1 (en) * 1991-10-10 1993-04-15 Merck Sharp & Dohme Limited Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors
AU2759692A (en) * 1991-10-24 1993-05-21 Glaxo Group Limited Benzodiazepine derivatives as antagonists of gastrin and/or cholecystokinin
GB2264492B (en) * 1992-02-27 1996-09-25 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives
IL104853A (en) * 1992-02-27 1997-11-20 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them
HUT68208A (en) * 1992-06-24 1995-06-28 Yamanouchi Pharma Co Ltd Novel benzodiazepine derivatives and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
HUT73978A (en) 1996-10-28
EP0715624A1 (en) 1996-06-12
JPH09504005A (ja) 1997-04-22
HU9600205D0 (en) 1996-04-29
FI960836A0 (fi) 1996-02-23
AU7466194A (en) 1995-03-21
FI960836A7 (fi) 1996-04-22
ZA946474B (en) 1996-03-25
EP0715624B1 (en) 1998-04-08
NZ271131A (en) 1997-11-24
GB2282595A (en) 1995-04-12
PL313165A1 (en) 1996-06-10
WO1995006040A1 (en) 1995-03-02
CA2169089A1 (en) 1995-03-02
CN1129442A (zh) 1996-08-21
ATE164840T1 (de) 1998-04-15
AU687433B2 (en) 1998-02-26
CZ53096A3 (en) 1996-09-11
NO960747L (no) 1996-04-25
DK0715624T3 (da) 1999-01-11
DE69409534D1 (de) 1998-05-14
IL110783A0 (en) 1994-11-11
DE69409534T2 (de) 1998-08-06
NO960747D0 (no) 1996-02-23
KR960703873A (ko) 1996-08-31
GB9317693D0 (en) 1993-10-13
US5728829A (en) 1998-03-17

Similar Documents

Publication Publication Date Title
ES2117797T3 (es) Procedimiento para la preparacion de compuestos de benzodiazepina utilizados como antagonistas de la cck o de la gastrina.
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
ES8603801A1 (es) Un metodo para preparar derivados de alcanoles aromaticos policiclicos
ES2098229T3 (es) Compuestos de pirazolopiridina y procedimientos para su preparacion.
ES2150918T3 (es) 1h-imidazo(4,5-c)quinolin-4-aminas 1-sustituidas; compuestos intermedios y composiciones farmaceuticas.
ES2154674T3 (es) Derivados de 1,5-benzodiacepinas con actividad antagonista o agonista de cck.
ES2121760T3 (es) Compuesto de pirazolopiridina y procedimiento para su preparacion.
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
ES2113656T3 (es) Pirazolopirimidinonas para el tratamiento de la impotencia.
HU907660D0 (en) Process for producing tricyclic compounds and pharmaceutical preparatives containing such compounds as active substances
ES2150577T3 (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
ES2196344T3 (es) Derivados de sulfonamida y su uso en el tratamiento de trastornos de snc.
CO5150176A1 (es) Antagonistas iii del receptor ccr-3 de los receptores ccr-3 composicio farmaceutica que los con- tiene y procedimiento para la preparacion de estos compues- tos.
UY24482A1 (es) Quinoxalinadionas
ES2095976T3 (es) Compuestos de pirazolopiridina y procedimiento para su preparacion.
MX9207335A (es) Nuevos derivados del acido fosfonosuccinico, procesos para su preparacion y composicion farmaceuticas que los contiene.
ATE346850T1 (de) 5-ht4-rezeptor-antagonisten
DK620784A (da) Nye tricykliske aminer
ES2104841T3 (es) Fosfono-aminoacidos bencimidazolicos.
ES2123560T3 (es) Composiciones farmaceuticas que comprenden derivados de hidroxamato para la eliminacion del hierro.
MX9304424A (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
ES2140181T3 (es) Androstenonas.
MX9301045A (es) Procedimiento para preparar antagonistas receptores de fibrinogeno.
ES2171646T3 (es) Uso de derivados de vinpocetina para la inhibicion o produccion de beta-proteina amiloide.
ES2091283T3 (es) Derivados de isocromano.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 715624

Country of ref document: ES